COPENHAGEN, Denmark — Novo Nordisk has made a significant leadership change as the pharmaceutical giant grapples with a slowdown in its weight-loss drug market. The company announced on Friday that CEO Lars Jørgensen is stepping down, a move that follows a steep decline in the company’s stock price amid growing competition in the sector.

The decision comes as Novo Nordisk faces increasing pressure from rivals, particularly Eli Lilly, whose own weight-loss products have gained traction in recent months. This intensified competition has prompted concerns about Novo’s ability to maintain its dominant position in a rapidly evolving market, raising questions about its future growth.

Jørgensen, who has helmed the company since 2021, has been credited with steering Novo through crucial phases, particularly in expanding its diabetes and obesity treatment portfolios. However, his tenure has recently been overshadowed by a slump in share values, with stock dropping significantly as investors voiced concerns over the company’s market strategy.

Novo Nordisk’s flagship weight-loss drug, Wegovy, was initially met with enthusiasm, capturing significant market interest and driving profits. Yet, as competitors like Eli Lilly introduced their own products, market dynamics shifted, and the pressure has mounted on Novo to adapt quickly to retain its customer base.

Industry analysts highlight the importance of strategic leadership during such critical transitions. They suggest that the appointment of new leadership is essential for revitalizing the company’s approach to R&D and product marketing. As the pharmaceutical landscape becomes increasingly competitive, companies must innovate rapidly to stay ahead of consumer demands.

Novo’s board is expected to prioritize finding a successor who can navigate this competitive terrain effectively. Potential candidates may bring fresh perspectives on leveraging advanced technologies and enhancing clinical trials to boost product efficacy and safety, essential factors that consumers and healthcare providers prioritize.

The leadership shake-up not only reflects internal company challenges but also illustrates broader trends in the pharmaceutical industry, where innovation and adaptability are crucial for survival. Companies that fail to keep pace may find themselves at a disadvantage as they compete for market share in lucrative sectors like obesity and diabetes treatments.

As Novo Nordisk embarks on this new chapter, stakeholders will be looking closely at how the company recalibrates its strategies and where it aims to steer its focus in the future. This change at the top is more than just a personnel issue; it signals the company’s commitment to overcoming immediate challenges in an ever-evolving market.